New cancer drug YL217 enters first human tests
NCT ID NCT06859762
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participants receive YL217 by IV infusion, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YL217 (an experimental drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is a very early, first-in-human Phase 1 trial, so the main goals are safety and finding the right dose. It is too soon to know if YL217 will shrink tumors or help patients live longer, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
-
Cleveland Clinic Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
-
Duke University Medical Center (DUMC)
RECRUITINGDurham, North Carolina, 27710, United States
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Bejing, 100730, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
-
The University of Kansas Cancer Center (KUCC)
RECRUITINGKansas City, Kansas, 66205, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
UCLA Hematology/Oncology - Santa Monica
RECRUITINGSanta Monica, California, 90404, United States
-
UT Health San Antonio - Mays Cancer Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
University of Cincinnati Medical Center
RECRUITINGCincinnati, Ohio, 45219, United States
-
University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
-
University of Wisconsin Health - UW Carbone Cancer Center
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06519, United States
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?